Program
givinostat
Also written as “Givinostat”, “ITF2357” and “ITF2357 10 mg/mL”.
Its studies are mostly in Muscular Dystrophy, Duchenne · Polycythemia Vera · Arthritis, Juvenile · Hodgkin Disease · Myeloproliferative Disorders, led by Italfarmaco.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Italfarmaco | 234 open or running | phase 3since Jul 27, 2016 | Jul 3, 2007 | Dec 2026phase 2 · NCT01761968 |
Also a collaborator on its studies: fortrea, biotrial, ppd-development-lp, cromsource and parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Jul 3, 2007.
- Jun 25, 2009Phase 2 study in Polycythemia VeraNCT00928707 · 45 enrolled · Italy
- Dec 15, 2010Phase 2 study in Arthritis, JuvenileNCT01261624 · 16 enrolled · Belgium, Czech Republic, Italy and more
- Mar 14, 2012No phase study in Arthritis, JuvenileNCT01557452 · 1 enrolled · Czechia
- Dec 18, 20122 phase 2 studiesNCT01761968, NCT01761292
- Jul 10, 2013Phase 2 study in Polycythemia VeraNCT01901432 · 48 enrolled · France, Germany, Italy and more
- Jul 27, 2016Phase 3 study in Muscular Dystrophy, DuchenneNCT02851797 · 179 enrolled · United States, Belgium, Canada and more
- Jul 12, 2017Phase 2 study in Muscular Dystrophy, DuchenneNCT03238235 · 51 enrolled · Italy, Netherlands
- Dec 4, 2017Phase 3 study in Muscular Dystrophy, DuchenneNCT03373968 · 206 planned · United States, Belgium, Canada and more
- Mar 26, 2021Phase 1 study in Muscular Dystrophy, DuchenneNCT04821063 · 31 enrolled · Canada
- Jun 9, 2022Phase 1 study in Drug-Drug InteractionNCT05492318 · 26 enrolled · Portugal
- Apr 26, 20232 phase 1 studies in Drug Drug InteractionNCT05860114, NCT05845567
- Jun 16, 2023Phase 3 study in Muscular Dystrophy, DuchenneNCT05933057 · 138 planned · Belgium, Canada, Czechia and more
- Oct 10, 2023Phase 3 study in Polycythemia VeraNCT06093672 · 220 planned · United States, Austria, Bulgaria and more
- Dec 6, 2024Phase 1 study in Hepatic ImpairmentNCT06736223 · 24 enrolled · Bulgaria, France
Ahead
- Dec 2026Primary completion: phase 2 study in Myeloproliferative DisordersNCT01761968
- Feb 2028Primary completion: phase 3 study in Muscular Dystrophy, DuchenneNCT05933057
- Dec 2029Primary completion: phase 3 study in Muscular Dystrophy, DuchenneNCT03373968
TargetBeta
“Histone deacetylase inhibitor”ChEMBL 37, by rule
Other programs on the same 11 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| givinostat hydrochloriderule | Italfarmaco | phase 2 | 1 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06736223Hepatic Impairment · Bulgaria, France | 1 | Completed | Aug 14, 2025 | 24 |
| NCT06093672Polycythemia Vera · United States, Austria, Bulgaria and more | 3 | Recruiting | Jul 2026 | 220 |
| NCT05933057Muscular Dystrophy, Duchenne · Belgium, Canada, Czechia and more | 3 | Recruiting | Feb 2028 | 138 |
| NCT05860114Drug Drug Interaction · Portugal | 1 | Completed | May 8, 2022 | 8 |
| NCT05845567Drug Drug Interaction · Portugal | 1 | Completed | May 8, 2022 | 20 |
| NCT05492318Drug-Drug Interaction · Portugal | 1 | Completed | May 8, 2022 | 26 |
| NCT04821063Muscular Dystrophy, Duchenne · Canada | 1 | Completed | Jun 18, 2021 | 31 |
| NCT03373968Muscular Dystrophy, Duchenne · United States, Belgium, Canada and more | 3 | Recruiting | Dec 2029 | 206 |
| NCT03238235Muscular Dystrophy, Duchenne · Italy, Netherlands | 2 | Completed | Mar 19, 2021 | 51 |
| NCT02851797Muscular Dystrophy, Duchenne · United States, Belgium, Canada and more | 3 | Completed | Feb 22, 2022 | 179 |
| NCT01901432Polycythemia Vera · France, Germany, Italy and more | 2 | Completed | Jun 26, 2017 | 48 |
| NCT01761292Muscular Dystrophy, Duchenne · Italy | 2 | Completed | Dec 2014 | 20 |
| NCT01761968Myeloproliferative Disorders · Germany, Italy, United Kingdom | 2 | Active, not recruiting | Dec 2026 | 90 |
| NCT01557452Arthritis, Juvenile · Czechia | – | Terminated | Jan 27, 2014 | 1 |
| NCT01261624Arthritis, Juvenile · Belgium, Czech Republic, Italy and more | 2 | Terminated | Jun 2012 | 16 |
| NCT00928707Polycythemia Vera · Italy | 2 | Completed | Jul 2011 | 45 |
| NCT00792467Hodgkin Disease · Italy | 2 | Completed | Jul 2010 | 24 |
| NCT00792831Leukemia, Lymphocytic, Chronic, B-Cell · Italy | 2 | Terminated | Apr 2009 | 3 |
| NCT00792740Crohn Disease · Belgium, Italy, Netherlands | 2 | Terminated | Dec 2008 | 51 |
| NCT00792506Multiple Myeloma · Italy | 2 | Terminated | Jan 2010 | 1 |
| NCT00606307Polycythemia Vera · Italy | 2 | Completed | Dec 2008 | 29 |
| NCT00570661Active Systemic · Romania, Serbia | 2 | Completed | Aug 25, 2008 | 17 |
| NCT00496431Hodgkin Disease · Italy | 2 | Terminated | Mar 2009 | 19 |
How it is read
Names in the registry
- “Givinostat”, 10 entries
- “ITF2357”, 7 entries
- “givinostat”, 2 entries
- “ITF2357 10 mg/mL”, 2 entries
- “Givinostat 10 mg/mL”, 1 entry
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 6 studies
- Polycythemia Vera, 4 studies
- Arthritis, Juvenile, 3 studies
- Hodgkin Disease, 2 studies
- Myeloproliferative Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.